1. Home
  2. SUPV vs OMER Comparison

SUPV vs OMER Comparison

Compare SUPV & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Supervielle S.A. each Representing five Class B shares

SUPV

Grupo Supervielle S.A. each Representing five Class B shares

HOLD

Current Price

$8.69

Market Cap

770.4M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$19.04

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPV
OMER
Founded
1887
1994
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
770.4M
844.6M
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
SUPV
OMER
Price
$8.69
$19.04
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$13.00
$32.50
AVG Volume (30 Days)
662.2K
2.2M
Earning Date
05-26-2026
05-14-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
$86.20
N/A
Revenue Next Year
$25.12
$233.22
P/E Ratio
N/A
$24.61
Revenue Growth
N/A
N/A
52 Week Low
$4.54
$3.94
52 Week High
$13.55
$19.65

Technical Indicators

Market Signals
Indicator
SUPV
OMER
Relative Strength Index (RSI) 50.77 71.42
Support Level $7.70 $18.00
Resistance Level $8.92 $19.65
Average True Range (ATR) 0.44 0.88
MACD 0.12 -0.14
Stochastic Oscillator 77.27 74.55

Price Performance

Historical Comparison
SUPV
OMER

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: